Charles River Laboratories Intl. Inc vs Hewlett Packard Enterprise Co — how do they compare? Charles River Laboratories Intl. Inc trades at $301.4 (market cap $14.23B), while Hewlett Packard Enterprise Co trades at $73.65 (market cap $94.25B). The key difference: Hewlett Packard Enterprise Co is far larger — about 6.6× Charles River Laboratories Intl. Inc's market cap, and Hewlett Packard Enterprise Co pays a 0.8% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Hewlett Packard Enterprise Co for 33 Days on average.
| CRL | HPE | |
|---|---|---|
Market Cap | $14.23B | $94.25B |
Volume | 1,176,885 | 16,060,854 |
Sector | Health | Technology |
52-Week High | $310.77 | $72.12 |
52-Week Low | $149.93 | $20.01 |
Typical Hold Time | 33 Days | 33 Days |
Enterprise Value | $17.06B | $108.28B |
Dividend Yield | — | 0.8% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $301.79, up 0.5% with strong analyst support (73% buy ratings) and a $305.50 consensus target. The stock shows bullish technical momentum above key support levels, though fundamentals reveal challenges with negative net income margins (-5.96%) and elevated P/E ratio (684.85). Recent quarterly earnings beats and a new 2030 growth strategy provide optimism, but profitability concerns persist amid flat revenue trends.
The outlook balances near-term technical strength against fundamental headwinds. Investment opportunity lies in execution of the 5-7% growth target and $300M savings plan, while risks include sustained negative profitability, high debt levels ($2.24B), and margin pressure. Current price near resistance at $304 suggests limited upside without fundamental improvement.
HPE trades at $73.46, up 1.87% today and near its 52-week high, driven by strong AI infrastructure demand. The stock has a bullish technical signal with moving averages supporting the uptrend. Recent earnings beats, including Q2 2026 EPS of $1.11 versus $0.932 expected, highlight operational strength. A $1.2 billion AI server order from Vultr and raised revenue guidance fuel optimism, though valuation ratios like a P/E of 36.6 suggest premium pricing.
Outlook remains positive with AI-driven growth catalysts, but risks include high valuation and competitive pressures. Analyst consensus is mixed with a $70.35 price target, slightly below current levels. Net income margin compression in 2025 to 0.16% warrants monitoring, though 2026 projections show recovery. The stock's momentum hinges on execution of AI orders and margin expansion.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Hewlett Packard Enterprise is an information technology vendor that provides hardware and software to enterprises. Its primary product lines are compute servers, storage arrays, and networking equipment.
Read more on HPE →